同时放化疗敏感性不同宫颈癌组织的二维电泳图谱建立及质谱分析

目的:分析同时放化疗后高敏感和低敏感中晚期宫颈癌组织之间蛋白质组的差异,为确定宫颈癌同时放化疗敏感性相关蛋白提供依据。方法:收集治疗前的中晚期宫颈癌活检组织标本,均为中分化鳞癌,置于—80℃超低温冰箱保存。同时放化疗后,根据WHO实体瘤疗效判断标准,将收集的10例宫颈癌组织标本分为高敏感组(5例)和低敏感组(5例);提取组织总蛋白,进行双向凝胶电泳(two-dimensional gel electrophoresis,2-DE)得到凝胶图谱,采用PD-quest 7.0软件进行匹配和差异分析,识别两组之间表达差异蛋白点。将部分差异蛋白点进行胶内原位酶解后进行MALDI-TOF-MS分析,获取肽质量指纹图,数据库搜索鉴定蛋白质。结果:建立了分辨率高,重复性好的同时放化疗后宫颈癌组织高敏感组和低敏感组的双向凝胶电泳图谱。高敏感组蛋白点数为781±74个,低敏感组蛋白点数为766±52个,组间平均匹配率为87.6%。质谱分析成功鉴定15个差异表达蛋白,其中7个蛋白质在高敏感组高表达,8个蛋白质在高敏感组低表达。结论:蛋白质2-DE图谱和质谱鉴定结果说明同时放化疗后高敏感组和低敏感组宫颈癌组织间存在蛋白质表达的差异,这些蛋白质可能与同时放化疗敏感性有关。     

应用蛋白质组学方法初步筛选与鼻咽癌放射敏感相关的蛋白

目的:通过筛选放射敏感性不同的鼻咽癌细胞中差异表达蛋白,以发现与鼻咽癌放射敏感相关的蛋白。方法:放射处理并结合流式细胞术检测及比较5-8F和6-10B细胞的放射敏感性。提取细胞总蛋白,进行双向凝胶电泳、MALDI-TOF肽质指纹图分析、质谱数据的蛋白质库搜寻鉴定。应用Western Blot检测细胞中蛋白质表达。应用免疫组织化学方法检测鼻咽癌组织中相关蛋白的表达。结果:双向凝胶电泳后对胶上的部分分辨较好的差异蛋白质点进行肽质谱指纹图分析和鉴定,在两种细胞中差异表达最为显著的蛋白质有9个。Western Blot证实CK19和P73在5-8F和6-10B表达与蛋白质组结果一致。P73在鼻咽癌放射敏感组和不敏感组中的表达阳性率分别为90%、57.5%,存在显著性差异。结论:放射敏感性不同的鼻咽癌细胞中存在一些差异表达蛋白,这些蛋白可能与鼻咽癌放射敏感性有关,其中P73可能成为放射敏感性预测的侯选标志物。     

应用蛋白质组学技术筛选胃癌耐药相关蛋白质

胃癌多药耐药性是临床胃癌化疗失败最主要的原因之一,但其分子机制仍然不太清楚.为了寻找新的胃癌耐药相关的蛋白质,揭示胃癌多药耐药的分子机制,以胃癌细胞SGC7901和长春新碱诱导的耐药胃癌细胞SGC7901/VCR为研究对象,应用二维凝胶电泳(two-dimensionalelectrophoresis,2-DE)技术分离两种细胞的总蛋白质,图像分析识别差异表达的蛋白质点,基质辅助激光解吸电离飞行时间质谱(matrix-assistedlaserdesorption/ionizationtimeofflightmassspectrometry,MALDI-TOF-MS)及电喷雾电离串联质谱(electrosprayionizationtandemmassspectrometry,ESI-Q-TOF)对差异表达的蛋白质点进行鉴定,蛋白质印迹和实时RT-PCR验证部分差异蛋白质在两株细胞中的表达水平,反义核酸转染技术分析HSP27(heatshockprotein27,HSP27)高表达与SGC7901/VCR耐药的相关性.得到了分辨率较高、重复性较好的两株细胞系的二维凝胶电泳图谱,质谱分析共鉴定了24个差异蛋白质点,蛋白质印迹和实时RT-PCR验证了部分差异蛋白的表达水平,反义寡核苷酸抑制HSP27表达能增加SGC7901/VCR对长春新碱的敏感性.研究结果不仅提示这些差异蛋白质如HSP27,Sorcin等可能与胃癌的多药耐药相关,而且为揭示胃癌细胞的多药耐药性产生机制提供了线索.     

cDNA阵列筛选结直肠癌化疗敏感性相关基因的初步研究

目的:筛选与结直肠癌中与化疗敏感性相关的基因,为结直肠癌化疗的个体化方案制定提供分子遗传学方面的依据.方法:收集结直肠癌新鲜组织标本,部分用于提取组织RNA和组织蛋白质,部分用于肿瘤药物敏感实验(MTT法).病理学诊断为中分化腺癌,根据药物敏感实验结果分为化疗高敏感组和化疗低敏感组,进行cDNA阵列实验比较筛选差异表达基因,Western Blot检测部分差异表达基因的表达情况.结果:通过肿瘤药物敏感实验结果得到对5-Fu+CF+L-OHP(氟脲嘧啶,亚叶酸钙,奥沙利铂)联合作用敏感的5例(高敏感组),不敏感的5例(低敏感组),cDNA阵列结果显示化疗高敏感组和低敏感组的差异表达基因其中有34个基因,其中差异表达显著的基因9个;叶酸多聚谷氨酸(FPGS)的表达在高敏感组中均高于低敏感组,HSP27在化疗低敏感组中的表达均高于高敏感组,与基因芯片中cDNA表达变化一致.结论:在结直肠腺癌化疗敏感性不同的病例中存在差异表达基因,这些基因可能成为结直肠癌化疗敏感性预测的生物标志物.     

高畸形率水牛精子与正常水牛精子差异表达蛋白的分离和鉴定

旨在分析高畸形率和正常水牛精子的差异表达蛋白.运用双向凝胶电泳以及基质辅助激光解吸电离飞行时间质谱(MALDI-TOF-MS/MS)分析鉴定出高畸形率和正常的水牛精子的差异表达蛋白,并对部分蛋白进行生物信息学分析.结果显示,高畸形率和正常水牛精子之间存在16个表达差异明显的蛋白点,与正常水牛精子相比,5个蛋白斑点表达量上调,6个蛋白斑点下调,3个蛋白斑点缺失,2个蛋白斑点在畸形率高的水牛精子特有.质谱鉴定16个差异蛋白,成功鉴定出6个差异蛋白斑点,对应4种蛋白:左旋天冬酰胺酶、热应激蛋白β-9、半乳糖激酶、β-微管蛋白-2C.研究表明,高畸形率和正常水牛精子蛋白质表达存在一定的差异.     

基于MALDI-TOF MS技术子宫内膜癌血清学诊断模型的建立及验证

目的:通过基质辅助激光解吸电离飞行时间质谱(MALDI-TOF MS)技术建立子宫内膜癌(EC)血清学诊断模型。方法:收集53例EC初诊患者和37例子宫内膜良性病变患者血清,按照2∶1随机分为训练组60例(EC患者35例,良性病变患者25例)和验证组30例(EC患者18例,良性病变患者12例);通过弱阳离子交换磁珠(MB-WCX)提取血清蛋白,经MALDI-TOF MS筛选差异蛋白。根据训练组中差异蛋白建立诊断模型,用验证组验证诊断模型的敏感性、特异性及诊断效率。结果:筛选出47个差异蛋白峰(P0.05),联合ROC曲线分析筛出AUC0.80的差异峰14个,其中在EC组表达上调的蛋白有7个;m/z分别为1779.63和1866.76 Da的2个蛋白峰差异性最显著,AUC分别为0.935和0.969,且EC组的平均峰值强度和峰下面积明显低于良性病变组。以上述2个蛋白建立诊断模型,经验证其敏感性为88.89%,特异性为91.67%,诊断效率为90%。结论:利用MALDI-TOF MS技术建立的EC血清学诊断模型有较高的敏感性和特异性,有望用于EC的早期筛查和辅助诊断。提示蛋白峰m/z 1779.63和1866.76 Da可能成为EC的潜在肿瘤标志物。     

血清TAP、TFF3与晚期胃癌患者含奥沙利铂化疗方案敏感性和预后的关系

摘要 目的：探讨血清肿瘤异常蛋白（TAP）、三叶因子3（TFF3）与晚期胃癌患者应用含奥沙利铂化疗方案敏感性和预后的关系。方法：选择2017年1月至2020年1月河北大学附属医院收治的115例晚期胃癌患者,所有患者接受含奥沙利铂化疗方案治疗,根据疗效分为敏感组（47例）和耐药组（68例）。化疗前检测血清TAP、TFF3水平,受试者工作特征（ROC）曲线分析TAP、TFF3预测晚期胃癌患者接受含奥沙利铂化疗疗效的价值。治疗后随访,Wilcoxon检验不同血清TAP、TFF3表达下晚期胃癌患者中位OS时间差异。结果：耐药组血清TAP、TFF3水平高于敏感组（P＜0.05）。TAP、TFF3预测晚期胃癌患者含奥沙利铂化疗耐药的曲线下面积分别为0.717、0.690,联合TAP和TFF3预测晚期胃癌患者含奥沙利铂化疗耐药的曲线下面积为0.801,高于单独TAP、TFF3单独检测。随访期间失访2例,死亡54例,高水平TAP、高水平TFF3晚期胃癌患者中位OS时间短于低水平TAP、低水平TFF3晚期胃癌患者（P＜0.05）。结论：对含奥沙利铂化疗耐药的晚期胃癌患者血清TAP、TFF3水平显著增高,高水平TAP、TFF3晚期胃癌患者中位OS时间较短,联合检测血清TAP和TFF3可预测晚期胃癌患者化疗反应性和预后。     

肝癌亚细胞结构的蛋白质组分比较分析

运用亚细胞蛋白质组学的研究策略,分离纯化亚细胞结构,可以提高低丰度蛋白质在双向电泳中检出的数量。通过对比分析肝癌细胞与正常肝细胞线粒体、细胞核蛋白质组的差异表达情况,为肝癌发病机理的研究提供更多、更有价值的信息。以体外培养的人体肝癌细胞QGY-7703与正常肝细胞LO2为研究模型,通过超离心的方法分离细胞的线粒体和细胞核。双向电泳分离线粒体和细胞核的蛋白质,图像分析筛选差异表达蛋白斑点,MALDI-TOF-MS鉴定蛋白质。从线粒体、细胞核的蛋白质电泳图谱中筛选出54个候选差异表达的蛋白质斑点,质谱鉴定出22种差异表达蛋白质,其中17种在肝癌细胞中表达上调,5种在肝癌细胞中表达下调。筛选出的差异表达蛋白质涉及到细胞的能量代谢、蛋白质合成、细胞骨架与核骨架的改变、mRNA的加工成熟及凋亡调控等许多方面,表明癌变细胞的组织结构和代谢状态都发生了很大的变化。     

优化硝酸银染色在心肌线粒体蛋白双向电泳后凝胶染色中的应用

蛋白组学研究中双向电泳(2-DE)后的SDS-PAGE凝胶染色存在灵敏度和质谱兼容性问题。线粒体中存在大量微量蛋白,对于这类亚细胞器蛋白质2-DE后的凝胶染色,这两种特性显得尤为重要。经典的硝酸银染色虽灵敏度高,但之后的质谱鉴定兼容性欠佳。因此,该研究通过优化硝酸银染色方法观察大鼠心肌线粒体蛋白质2-DE后的凝胶染色效果,挖取部分蛋白质斑点酶解后行基质辅助激光解吸电离飞行时间质谱(MALDI-TOF-MS)鉴定,验证优化硝酸银染色与质谱鉴定的兼容性。结果表明,优化后的硝酸银染色方法灵敏度高,与MALDI-TOF-MS兼容性好,是一种线粒体蛋白质2-DE后染色的理想方法。     

Ezrin在化疗敏感性不同大B细胞淋巴瘤中表达的实验研究

目的：比较化疗敏感性不同弥漫性大B细胞淋巴瘤的蛋白质表达差异,寻找可反映大B细胞淋巴瘤化疗敏感性的标志物。方法：通过肿瘤药物敏感试验选取化疗高敏感性和低敏感性大B细胞淋巴瘤组织,进行蛋白质组学比较研究后得出差异表达蛋白;对在高敏感组中高表达的埃兹蛋白（Ezrin）进一步行免疫印迹验证,应用免疫组化技术检测在临床病例中的表达情况。结果：建立了化疗高敏感和低敏感大B细胞淋巴瘤差异表达蛋白质凝胶2D图谱,鉴定了28种差异表达蛋白,发现Ezrin蛋白在化疗高敏感组表达高于低敏感组,免疫印迹和免疫组化结果也进一步证实了Ezrin的这一表达状态。结论：Ezrin蛋白表达在化疗敏感性不同大B细胞淋巴瘤中存在差别,可能作为预测淋巴瘤化疗敏感性的候选标志物。     

Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel

Background

The luminal A subtype of breast cancer has a good prognosis and is sensitive to endocrine therapy but is less sensitive to chemotherapy. It is necessary to identify biomarkers to predict chemosensitivity and avoid over-treatment. We hypothesized that miRNAs in the serum might be associated with chemosensitivity.

Methods

Sixty-eight breast cancer patients received neoadjuvant chemotherapy with epirubicin plus paclitaxel. The serum of the patients was collected before chemotherapy and stored at −80°C. The samples were classified into two groups in term of the chemosensitivity. We identified the differential expression patterns of miRNAs between the chemotherapy sensitive and resistant groups using microRNA profiling. Four miRNAs that were differentially expressed between the two groups were further validated in another 56 samples. We created a model fitting formula and a receiver operating characteristics (ROC) curve using logistic regression analysis to evaluate the prediction potency.

Results

We identified 8 miRNAs differentially expressed between the two groups: 6 miRNAs were up-regulated, and 2 miRNAs were down-regulated in the resistant group compared with the sensitive group. The expression of miR-19a and miR-205 were determined to have significant differences between the two groups (P<0.05). A predictive model of these two miRNAs was created by the logistic regression analysis. The probability of this model was 89.71%. Based on the ROC curve, the specificity was 75.00%, and the sensitivity was 81.25%.

Conclusions

The combination of miR-19a and miR-205 in the serum may predict the chemosensitivity of luminal A subtype of breast cancer to epirubicin plus paclitaxel neoadjuvant chemotherapy.     

Prediction of response and adverse drug reaction of pemetrexed plus platinum-based chemotherapy in lung adenocarcinoma by serum metabolomic profiling

BackgroundPemetrexed plus platinum doublet chemotherapy regimen remains to be the standard first-line treatment for lung adenocarcinoma patients. However, few biomarkers can be used to identify potential beneficiaries with maximal efficacy and minimal toxicity. This study aimed to explore potential biomarker models predictive of efficacy and toxicity after pemetrexed plus platinum chemotherapy based on metabolomics profiling.MethodsA total of 144 patients who received at least two cycles of pemetrexed plus platinum chemotherapy were enroled in the study. Serum samples were collected before initial treatment to perform metabolomics profiling analysis. Logistic regression analysis was performed to establish prediction models.Results157 metabolites were found to be differentially expressed between the response group and the nonresponse group. A panel of Phosphatidylserine 20:4/20:1, Sphingomyelin d18:1/18:0, and Phosphatidic Acid 18:1/20:0 could predict pemetrexed and platinum chemotherapy response with an Area Under the Receiver Operating Characteristic curve (AUROC) of 0.7968. 76 metabolites were associated with hematological toxicity of pemetrexed plus platinum chemotherapy. A panel incorporating triglyceride 14:0/22:3/22:5, 3-(3-Hydroxyphenyl) Propionate Acid, and Carnitine C18:0 was the best predictive ability of hematological toxicity with an AUROC of 0.7954. 54 differential expressed metabolites were found to be associated with hepatotoxicity of pemetrexed plus platinum chemotherapy. A model incorporating stearidonic acid, Thromboxane B3, l-Homocitrulline, and phosphoinositide 20:3/18:0 showed the best predictive ability of hepatotoxicity with an AUROC of 0.8186.ConclusionsThis study established effective and convenient models that can predict the efficacy and toxicity of pemetrexed plus platinum chemotherapy in lung adenocarcinoma patients before treatment delivery.     

A serum protein profile predictive of the resistance to neoadjuvant chemotherapy in advanced breast cancers

Prediction of the responses to neoadjuvant chemotherapy (NACT) can improve the treatment of patients with advanced breast cancer. Genes and proteins predictive of chemoresistance have been extensively studied in breast cancer tissues. However, noninvasive serum biomarkers capable of such prediction have been rarely exploited. Here, we performed profiling of N-glycosylated proteins in serum from fifteen advanced breast cancer patients (ten patients sensitive to and five patients resistant to NACT) to discover serum biomarkers of chemoresistance using a label-free liquid chromatography-tandem MS method. By performing a series of statistical analyses of the proteomic data, we selected thirteen biomarker candidates and tested their differential serum levels by Western blotting in 13 independent samples (eight patients sensitive to and five patients resistant to NACT). Among the candidates, we then selected the final set of six potential serum biomarkers (AHSG, APOB, C3, C9, CP, and ORM1) whose differential expression was confirmed in the independent samples. Finally, we demonstrated that a multivariate classification model using the six proteins could predict responses to NACT and further predict relapse-free survival of patients. In summary, global N-glycoproteome profile in serum revealed a protein pattern predictive of the responses to NACT, which can be further validated in large clinical studies.     

Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines

Chemoresistance is a major therapeutic obstacle in cancer patients, and the mechanisms of drug resistance are not fully understood. In the present study, we established platinum-resistant human ovarian cancer cell lines and identified differentially expressed proteins related to platinum resistance. The total proteins of two sensitive (SKOV3 and A2780) and four resistant (SKOV3/CDDP, SKOV3/CBP, A2780/CDDP, and A2780/CBP) human ovarian cancer cell lines were isolated by two-dimensional gel electrophoresis (2-DE). The differentially expressed proteins were identified using matrix-assisted laser desorption ionization-time-of-flight mass spectrometry (MALDI-TOF MS). In total, 57 differential protein spots were identified, and five proteins, including annexin A3, destrin, cofilin 1, Glutathione-S-transferase omega 1 (GSTO1-1), and cytosolic NADP+-dependent isocitrate dehydrogenase (IDHc), were found to be co-instantaneous significance compared with their parental cells. The expression of the five proteins was validated by quantitative PCR and western blot, and the western blot results showed complete consistency with proteomic techniques. The five proteins are hopeful to become candidates for platinum resistance. These may be useful for further study of resistance mechanisms and screening of resistant biomarkers.     

急性早幼粒细胞白血病维甲酸耐药性的双向电泳分析

目的:研究急性早幼粒细胞白血病(APL)对全反式维甲酸(ATRA)治疗敏感和耐药患者的外周血淋巴细胞在蛋白质组水平上的差异。方法:采用双向凝胶电泳(2-DE)对敏感和耐药患者的外周血淋巴细胞进行蛋白质组差异分析。结果:ATRA敏感和耐药患者外周血淋巴细胞的2-DE平均蛋白质点分别为(746±57)和(617±41),敏感与耐药患者的2-DE相比,有16个蛋白点表达明显上调,22个明显下调。另有4个蛋白点(Mr/pI:24.6kD/8.05,32.3kD/5.17,22.3kD/6.51,25.1kD/7.09)在敏感患者中特异表达,5个蛋白点(Mr/pI:21.9kD/5.45,23.4kD/6.27,22.9kD/6.65,23.9kD/7.39,24.7kD/7.65)在耐药患者中特异表达。结论:结果提示这些差异表达的蛋白质可能与APL对ATRA耐药的机制有关,该研究有助于揭示APL对ATRA耐药机理和发现新的临床分子标志物。     

Serum differential protein identification of Xinjiang Kazakh esophageal cancer patients based on the two-dimensional liquid-phase chromatography and LTQ MS

The aim of this study was to investigate the impact of chemo-radiotherapy on serum protein expression of the esophageal cancer patients and discover potential biomarkers by detecting serum proteins mass spectrometry of the healthy Kazakh people in Xinjiang as well as the patients before and after their chemo-radiotherapy. In order to separate and compare the three serum samples (the healthy group’s, the patients’ before and after chemo-radiotherapy) with two-dimensional protein liquid chromatography system (Proteome LabTM PF-2D), then detect the differential protein spots with linear trap quadruple mass spectrometer (LTQ MS/MS). (1) The Kazakh esophageal cancer patients got 21 expressed protein spots peaks with significant difference after chemo-radiotherapy compared with before; before the treatment there were 10 different expressed protein spots compared with the healthy group, and after it there were four peaks in the expression of protein spots compared with the healthy group. (2) After LTQ mass spectrometric detection, 22 proteins were up-regulated in serum samples of the healthy group, 22 were up-regulated of the patients before medical treatment and 5 were up-regulated after chemo-radiotherapy. (3) 8 proteins including APOA1 can be served as serum markers in Kazakh esophageal cancer diagnosis, and proteins like CLU can be served as serum markers in judging the resistance and sensitivity towards chemo-radiotherapy. (4) The abnormal expressions of APOC2, APOC3, Antithrombin-III in esophageal cancer were discovered for the first time. Specific protein spots related to Xinjiang Kazakh esophageal cancer diagnosis and chemo-radiotherapy can be identified in the serum, which will probably become a maker in Kazakh esophageal cancer diagnosis and therapeutic evaluation.     

TECIA法体外药敏试验对食管癌术后化疗个体化方案选择的研究

目的：通过实体瘤体外药敏试验以期指导食管癌术后化疗方案的选择,实现食管癌化疗个体化用药。方法：采用TECIA法对319例肿瘤组织标本进行体外组织培养,并用常见九种化疗药物进行药物敏感性试验,根据试验结果选用化疗方案进行术后辅助化疗。结果：319份标本对常见化疗药高敏感占2．4％,中敏感占48．6％;传统化疗方案药物部分呈现低度敏感,甚至耐药现象;根据药敏结果选用中、高敏感药物进行术后化疗其5年生存期明显延长,复发率降低。结论：肿瘤药物敏感试验对指导患者的个体化治疗具有重要的价值。     

长期中小强度有氧运动对大鼠左心室肌蛋白质组差异表达的影响*

目的:探讨长期中小强度有氧运动对大鼠左室肌蛋白质组差异性表达的影响,筛选出对中小强度有氧运动刺激敏感的目标蛋白质,丰富运动健身的基础理论及为慢性心血管疾病的康复治疗提供新的思路和实验依据。方法:20只雄性SD大鼠随机分为运动组(E组)和对照组(C组)(n=10)。建立大鼠长期中小强度有氧运动跑台训练模型,采用双向凝胶电泳(2-DE)对大鼠左心室肌全蛋白样品进行分离。采用串联飞行时间质谱蛋白质仪对部分分离后差异表达量上调大于5倍或下调超过80%的蛋白质点进行质谱鉴定。结果:与C组比较,E组大鼠心脏重量指数(HWI)增加了32.0%,具有显著性差异(P＜0.05);与C组比较,E组有71个蛋白质点表达上调≥2倍或下调≥50%,对4个表达上调≥5倍或下调大于等于80%的蛋白质点进行质谱鉴定,鉴定出3个蛋白质和1个未知蛋白质。结论:长期中小强度有氧运动后,大鼠心脏发生了良好的适应性改变;大鼠左心室肌蛋白质组发生了明显变化,长期中小强度有氧运动能有效增强大鼠心肌抗氧化能力。     

GDF15基因在卵巢上皮性癌组织中的表达及其临床意义

目的:探讨生长分化因子GDF15(Growth Differentiation Factor 15)基因在卵巢上皮性癌组织中的表达及其与铂类耐药的相关性。方法:应用免疫组化、western blot、RT-PCR等方法对80例原发性卵巢癌组织和卵巢癌顺铂敏感/耐药株A2780和CP70、SKOV3和SKOV3/DDP中生长分化因子GDF15表达水平进行测定。结果:生长分化因子GDF15的表达强度与卵巢癌铂类耐药性显著相关。在卵巢癌顺铂耐药株CP70、SKOV3/DDP中GDF15表达水平较顺铂敏感株A2780、SKOV3明显增高。结论:GDF15表达水平与卵巢癌发生发展及铂类耐药相关,对于卵巢癌患者早期筛选、预测预后具有一定的临床指导价值。